SGCB and chronic kidney disease: We have chosen low dosage of both drugs with moderate but comparable blood pressure effects in an aggressive CKD model characterized by pronounced kidney fibrosis to explore potential underlying differences in the molecular mechanisms of sGC activators versus stimulator using a non-hypothesis driven approach: proteomics.